Koers Genovis AB (publ.) Nasdaq Stockholm
Aandelen
SE0002485979
Medische apparatuur, benodigdheden & distributie
Omzet 2024 * | 155 mln. 14,5 mln. 13,32 mln. | Omzet 2025 * | 238 mln. 22,35 mln. 20,53 mln. | Marktkapitalisatie | 2,09 mld. 196 mln. 180 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 38 mln. 3,56 mln. 3,27 mln. | Nettowinst (verlies) 2025 * | 38 mln. 3,56 mln. 3,27 mln. | EV/omzet 2024 * | 12,7 x |
Nettoliquiditeiten 2024 * | 120 mln. 11,29 mln. 10,37 mln. | Nettoliquiditeiten 2025 * | 95,5 mln. 8,96 mln. 8,23 mln. | EV/omzet 2025 * | 8,38 x |
K/w-verhouding 2024 * |
54,4
x | K/w-verhouding 2025 * |
24,1
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 95,42% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-01-02 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 01-01-22 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 72 | 05-05-20 | |
Director/Board Member | 63 | 01-01-19 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 01-01-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-4,62% | 12,18 mld. | |
+8,48% | 5,96 mld. | |
+28,39% | 5,45 mld. | |
-6,28% | 4,34 mld. | |
-52,84% | 3,18 mld. | |
+12,93% | 2,75 mld. | |
+28,84% | 2,3 mld. | |
-3,80% | 2,28 mld. | |
-4,64% | 1,92 mld. |